News of Note—Turnstone-La Jolla pact, Inovio-GeneOne and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Under a new collaboration, Turnstone Biologics will use La Jolla Institute for Allergy and Immunology’s neoantigen identification methods to select personalized neoantigens for the development of cancer immunotherapies. Release

> Inovio and GeneOne Life Science have dosed the first patient in a phase 1 study of GLS-6150, a vaccine that aims to boost patients’ immunity against hepatitis C. Drug Development Technology article

> After posting positive topline results, Altimmune reported that its NasoVAX intranasal influenza vaccine candidate demonstrated a durable immune response for at least six months, while significant mucosal antibodies were also observed. Release

> A team at the University of California, San Diego, is developing an acne vaccine which has passed studies on animals and human acne samples. It’s seeking a company to collaborate on a clinical trial. U.S. News & World Report article

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.